Inequities Seen in GLP-1 RA Use for Type 2 Diabetes in the U.S.
Asian, Black, Hispanic, and low-income patients less likely to receive treatment with a glucagon-like peptide-1 receptor agonist for T2DM
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.